You are here: Industry Insights > oncology

News List

Nimbus Therapeutics, Charles River in Strategic R&D Alliance contractpharma
April 07, 2017
Will work to advance programs in immunology, metabolic disorders and oncology from discovery through to IND
Charles River Launches Oncology Research Model contractpharma
April 05, 2017
Charles River Laboratories has launched its triple-immunodeficient mouse model, known as the NCG model. The NCG model is the first CRISPR-generated immunodeficient model offered by the company, and was developed by altering the Prkdc and Il2rg genes.
SGS Expands Hospital Clinical Pharmacology Network contractpharma
March 15, 2017
Establishes Phase I patient unit at Medical Center of Defense Hospital in Budapest, Hungary
Selvita to Present New Data from its Oncology Programs at the Upcoming AACR Annual Meeting 2017 b3cnewswire
March 14, 2017
Selvita a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the upcoming AACR Annual Meeting 2017.
Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC drugs.com
March 13, 2017
Radius Health announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for Abaloparatide-SC.
The Value of Innovation in Oncology lilly
March 10, 2017
This post comes from Lydia Makaroff, Director, and Francesco Florindi, Head of EU Affairs, of the European Cancer Patient Coalition.
German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines b3cnewswire
March 09, 2017
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer
First biosimilar mAb in oncology granted EU approval europeanpharmaceuticalreview
February 24, 2017
The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union.
Mundipharma expands oncology portfolio biospectrumasia
February 20, 2017
Mundipharma has acquired all the rights for marketing, promotion, distribution and sales of ALOXI and AKYNZEO for an additional 30 countries
Stemline Therapeutics Prices $45 Million Public Offering of Common Stock firstwordpharma
January 23, 2017
Stemline Therapeutics, Inc. (Nasdaq:STML) announced the pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, with expected gross proceeds to Stemline of $45 million.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 18 19 Next page